ATAD3A and neoplasm: Paclitaxel upregulates ATAD3A to suppress mitophagy-mediated recruitment and subsequent degradation of PD-L1 protein, resulting in its excessive accumulation on cell membrane to markedly enhance tumor-induced immune deficiency.